New gout treatment shows promise in small trial
NCT ID NCT05925166
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called rhTNFR-Fc (similar to etanercept) combined with methylprednisolone in 26 adults with acute gout. The goal was to see if it safely reduces joint pain and delays the next flare-up. Participants received two injections over five days, and researchers measured pain levels and recurrence time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- etanercept (rhTNFR-Fc) and methylprednisolone
- What this could lead to
- If it works, this could offer a new option to quickly relieve pain and prevent gout flare-ups.
- What could go wrong
- This was a very small, early-stage study with only 26 people. Results may not apply to everyone, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Rheumatology and Clinical Immunology, Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, 330000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.